From Yahoo Finance: 2025-05-09 11:11:00

In Q1 earnings news, Compass Pathways (CMPS) reported a loss per share of (24c), beating analyst estimates of (49c). Cash and cash equivalents were $260.1M as of March 31. GH Research (GHRS) also reported a Q1 loss of (19c) with $315.3M in cash and cash equivalents. Mind Medicine (MNMD) reported a loss of (35c) with $245.5M in cash.

Cybin (CYBN) received a U.S. patent grant for its CYB003 program in Major Depressive Disorder. MIRA Pharmaceuticals (MIRA) reported positive neurotoxicity results for Ketamir-2. MIRA also approved the acquisition of SKNY Pharmaceuticals. Chardan initiated coverage of Bright Minds (DRUG) with a Buy rating and $80 price target.

NRx Pharmaceuticals (NRXP) filed a patent application for NRX-100, its intravenous ketamine formulation for suicidal depression. Publicly-traded psychedelic stocks include Algernon Pharmaceuticals (AGNPF), Allied Corp. (ALID), and many others. MIRA’s acquisition of SKNY remains subject to shareholder approval.

Read more: Compass, GH Research, MindMed report quarterly earnings